Secondary amyloidosis natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
In amyloidosis, insoluble fibrils of [[amyloid]] are deposited in [[organs]], causing [[Multiple organ dysfunction syndrome|organ dysfunction]] and eventually death. [[Patient|Patients]] with amyloidosis may eventually suffer from [[heart failure]], [[nephrotic syndrome]], [[hepatomegaly]] and [[peripheral neuropathy]]. | In amyloidosis, insoluble fibrils of [[amyloid]] are deposited in [[organs]], causing [[Multiple organ dysfunction syndrome|organ dysfunction]] and eventually death. [[Patient|Patients]] with amyloidosis may eventually suffer from [[heart failure]], [[nephrotic syndrome]], [[hepatomegaly]] and [[peripheral neuropathy]]. [[Prognosis]] is poor and 5-years [[survival rate]] is 51.3%.[[Infection]] and [[renal failure]] are the most common cause of death. | ||
==Natural History, Complications, and Prognosis== | ==Natural History, Complications, and Prognosis== | ||
=== Natural History === | === Natural History === | ||
*In amyloidosis, insoluble fibrils of [[amyloid]] are deposited in the organs, causing organ dysfunction | *In amyloidosis, insoluble fibrils of [[amyloid]] are deposited in the organs, causing organ dysfunction.<ref name="LachmannGoodman2007">{{cite journal|last1=Lachmann|first1=Helen J.|last2=Goodman|first2=Hugh J.B.|last3=Gilbertson|first3=Janet A.|last4=Gallimore|first4=J. Ruth|last5=Sabin|first5=Caroline A.|last6=Gillmore|first6=Julian D.|last7=Hawkins|first7=Philip N.|title=Natural History and Outcome in Systemic AA Amyloidosis|journal=New England Journal of Medicine|volume=356|issue=23|year=2007|pages=2361–2371|issn=0028-4793|doi=10.1056/NEJMoa070265}}</ref> | ||
*[[Patient|Patients]] with amyloidosis may eventually suffer from | *[[Patient|Patients]] with amyloidosis may eventually suffer from [[nephrotic syndrome]], [[renal failure]], and [[death]]. | ||
===Complications=== | ===Complications=== | ||
*In patients with amyloidosis, the most frequent [[complications]] include:<ref name="pmid26155101">{{cite journal |vauthors=Jerzykowska S, Cymerys M, Gil LA, Balcerzak A, Pupek-Musialik D, Komarnicki MA |title=Primary systemic amyloidosis as a real diagnostic challenge - case study |journal=Cent Eur J Immunol |volume=39 |issue=1 |pages=61–6 |date=2014 |pmid=26155101 |pmc=4439975 |doi=10.5114/ceji.2014.42126 |url=}}</ref> | |||
In patients with amyloidosis, the most frequent [[complications]] include:<ref name="pmid26155101">{{cite journal |vauthors=Jerzykowska S, Cymerys M, Gil LA, Balcerzak A, Pupek-Musialik D, Komarnicki MA |title=Primary systemic amyloidosis as a real diagnostic challenge - case study |journal=Cent Eur J Immunol |volume=39 |issue=1 |pages=61–6 |date=2014 |pmid=26155101 |pmc=4439975 |doi=10.5114/ceji.2014.42126 |url=}}</ref> | **[[Nephrotic syndrome]], the most common | ||
**[[Hepatomegaly]] | |||
* | **[[Peripheral neuropathy]] | ||
*[[Nephrotic syndrome]] | **[[Heart failure]] | ||
*[[Hepatomegaly]] | |||
*[[Peripheral neuropathy]] | |||
===Prognosis=== | ===Prognosis=== | ||
* [[Prognosis]] is | * [[Prognosis]] is poor and 5-years [[survival rate]] is 51.3%.<ref name="pmid25364365">{{cite journal |vauthors=Ahbap E, Kara E, Sahutoglu T, Basturk T, Koc Y, Sakaci T, Sevinc M, Akgol C, Ucar ZA, Kayalar AO, Bayraktar F, Ozagari AA, Unsal A |title=Outcome of 121 patients with renal amyloid a amyloidosis |journal=J Res Med Sci |volume=19 |issue=7 |pages=644–9 |date=July 2014 |pmid=25364365 |pmc=4214024 |doi= |url=}}</ref> | ||
* Following factors are associated with higher rates of [[mortality]]: | * Following factors are associated with higher rates of [[mortality]]: | ||
** Older age | ** Older age | ||
| Line 31: | Line 27: | ||
** Higher levels of [[phosphor]] with intact [[parathyroid hormone]] | ** Higher levels of [[phosphor]] with intact [[parathyroid hormone]] | ||
* It has been reported that, survival rate is not affected by the underlying etiology.<ref name="pmid29173691">{{cite journal |vauthors=Ayar Y, Ersoy A, Oksuz MF, Ocakoglu G, Vuruskan BA, Yildiz A, Isiktas E, Oruc A, Celikci S, Arslan I, Sahin AB, Güllülü M |title=Clinical outcomes and survival in AA amyloidosis patients |journal=Rev Bras Reumatol Engl Ed |volume=57 |issue=6 |pages=535–544 |date=2017 |pmid=29173691 |doi=10.1016/j.rbre.2017.02.002 |url=}}</ref> | * It has been reported that, survival rate is not affected by the underlying etiology.<ref name="pmid29173691">{{cite journal |vauthors=Ayar Y, Ersoy A, Oksuz MF, Ocakoglu G, Vuruskan BA, Yildiz A, Isiktas E, Oruc A, Celikci S, Arslan I, Sahin AB, Güllülü M |title=Clinical outcomes and survival in AA amyloidosis patients |journal=Rev Bras Reumatol Engl Ed |volume=57 |issue=6 |pages=535–544 |date=2017 |pmid=29173691 |doi=10.1016/j.rbre.2017.02.002 |url=}}</ref> | ||
* [[Infection]] and [[renal failure]] are the most common cause of death. | |||
* Median [[survival]] has been reported between 6 to 9 years.<ref name="LachmannGoodman2007">{{cite journal|last1=Lachmann|first1=Helen J.|last2=Goodman|first2=Hugh J.B.|last3=Gilbertson|first3=Janet A.|last4=Gallimore|first4=J. Ruth|last5=Sabin|first5=Caroline A.|last6=Gillmore|first6=Julian D.|last7=Hawkins|first7=Philip N.|title=Natural History and Outcome in Systemic AA Amyloidosis|journal=New England Journal of Medicine|volume=356|issue=23|year=2007|pages=2361–2371|issn=0028-4793|doi=10.1056/NEJMoa070265}}</ref> | |||
* The most important predictable factor for development of [[renal failure]] and death is higher production of SAA. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Latest revision as of 19:22, 31 October 2019
|
Secondary amyloidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Secondary amyloidosis natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Secondary amyloidosis natural history, complications and prognosis |
|
FDA on Secondary amyloidosis natural history, complications and prognosis |
|
CDC on Secondary amyloidosis natural history, complications and prognosis |
|
Secondary amyloidosis natural history, complications and prognosis in the news |
|
Blogs on Secondary amyloidosis natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2] Sahar Memar Montazerin, M.D.[3]
Overview
In amyloidosis, insoluble fibrils of amyloid are deposited in organs, causing organ dysfunction and eventually death. Patients with amyloidosis may eventually suffer from heart failure, nephrotic syndrome, hepatomegaly and peripheral neuropathy. Prognosis is poor and 5-years survival rate is 51.3%.Infection and renal failure are the most common cause of death.
Natural History, Complications, and Prognosis
Natural History
- In amyloidosis, insoluble fibrils of amyloid are deposited in the organs, causing organ dysfunction.[1]
- Patients with amyloidosis may eventually suffer from nephrotic syndrome, renal failure, and death.
Complications
- In patients with amyloidosis, the most frequent complications include:[2]
- Nephrotic syndrome, the most common
- Hepatomegaly
- Peripheral neuropathy
- Heart failure
Prognosis
- Prognosis is poor and 5-years survival rate is 51.3%.[3]
- Following factors are associated with higher rates of mortality:
- It has been reported that, survival rate is not affected by the underlying etiology.[4]
- Infection and renal failure are the most common cause of death.
- Median survival has been reported between 6 to 9 years.[1]
- The most important predictable factor for development of renal failure and death is higher production of SAA.
References
- ↑ 1.0 1.1 Lachmann, Helen J.; Goodman, Hugh J.B.; Gilbertson, Janet A.; Gallimore, J. Ruth; Sabin, Caroline A.; Gillmore, Julian D.; Hawkins, Philip N. (2007). "Natural History and Outcome in Systemic AA Amyloidosis". New England Journal of Medicine. 356 (23): 2361–2371. doi:10.1056/NEJMoa070265. ISSN 0028-4793.
- ↑ Jerzykowska S, Cymerys M, Gil LA, Balcerzak A, Pupek-Musialik D, Komarnicki MA (2014). "Primary systemic amyloidosis as a real diagnostic challenge - case study". Cent Eur J Immunol. 39 (1): 61–6. doi:10.5114/ceji.2014.42126. PMC 4439975. PMID 26155101.
- ↑ Ahbap E, Kara E, Sahutoglu T, Basturk T, Koc Y, Sakaci T, Sevinc M, Akgol C, Ucar ZA, Kayalar AO, Bayraktar F, Ozagari AA, Unsal A (July 2014). "Outcome of 121 patients with renal amyloid a amyloidosis". J Res Med Sci. 19 (7): 644–9. PMC 4214024. PMID 25364365.
- ↑ Ayar Y, Ersoy A, Oksuz MF, Ocakoglu G, Vuruskan BA, Yildiz A, Isiktas E, Oruc A, Celikci S, Arslan I, Sahin AB, Güllülü M (2017). "Clinical outcomes and survival in AA amyloidosis patients". Rev Bras Reumatol Engl Ed. 57 (6): 535–544. doi:10.1016/j.rbre.2017.02.002. PMID 29173691.